Highlights from the 2025 Menopause Society Annual Meeting: Research & Treatment Updates
- Dr. Rochelle Bernstein
- Nov 5, 2025
- 4 min read
Updated: Dec 8, 2025
The 2025 Annual Meeting of The Menopause Society, held October 21–25 in Orlando, covered the latest research updates on perimenopause symptoms, menopause treatments, sexual health, brain function, bone health, and sleep. This patient-focused recaps the key highlights and what they could mean for your health.
1. Updates on Non-Hormonal Menopause Treatment: Lynkuet (Elinzanetant) for Hot Flashes
Hot flashes and night sweats are among the most common and disruptive menopause symptoms. Lynkuet (elinzanetant), a dual neurokinin 1 and 3 (NK1,3) receptor antagonist, was FDA-approved in late October 2025 for moderate to severe hot flashes. For comparison, Veozah (fezolinetant), already on the market, blocks only NK3 receptors. Both work in the brain’s thermoregulatory center to help reduce hot flashes.
Want to read more?
Subscribe to purelymenopause.com to keep reading this exclusive post.